Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy

Cancer Discovery

Volumn 5, Issue 9, 2015, Pages 988-1003

  Behbehani, Gregory K ^a,b   Samusik, Nikolay ^a   Bjornson, Zach B ^a   Fantl, Wendy J ^a   Medeiros, Bruno C ^a,b   Nolan, Garry P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD99 ANTIGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BARCODING; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INTRACELLULAR SIGNALING; MYELODYSPLASTIC SYNDROME; RECURRENCE RISK; BONE MARROW CELL; BONE MARROW EXAMINATION; CANCER STEM CELL; CELL CYCLE; CLUSTER ANALYSIS; GENETICS; GENOTYPE; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; PHENOTYPE; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BONE MARROW CELLS; BONE MARROW EXAMINATION; CELL CYCLE; CLUSTER ANALYSIS; FLOW CYTOMETRY; GENOTYPE; HUMANS; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84941754980     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0298     Document Type: Article

References (50)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907.
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322-33.
3. Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012;30:4515-23.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
5. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, et al. Aberrant marker expression patterns on the CD34+CD38stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007;21:1700-7.
6. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A clinically relevant population of leukemic CD34+CD38- cells in acute myeloid leukemia. Blood 2012;119:3571-7.
7. Terpstra W, Ploemacher RE, Prins A, van Lom K, Pouwels K, Wognum AW, et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 1996;88:1944-50.
8. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003;101:3142-9.
9. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotech 2007;25:1315-21.
10. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A 1999;96:3120-5.
11. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup. J Clin Oncol 2004;22:3741-50.
12. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 Trial. J Clin Oncol 2011;29:369-77.
13. Chou S-C, Tang J-L, Hou H-A, Chou W-C, Hu F-C, Chen C-Y, et al. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leuk Res 2014;38:1278-84.
14. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74.
15. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-89.
16. Behbehani GK, Bendall SC, Clutter MR, Fantl WJ, Nolan GP. Singlecell mass cytometry adapted to measurements of the cell cycle. Cytometry A 2012;81:552-66.
17. Behbehani GK, Thom C, Zunder ER, Finck R, Gaudilliere B, Fragiadakis GK, et al. Transient partial permeabilization with saponin enables cellular barcoding prior to surface marker staining. Cytometry A 2014;85:1011-9.
18. Zunder ER, Finck R, Behbehani GK, Amir E-aD, Krishnaswamy S, Gonzalez VD, et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat Protocols 2015;10:316-33.
19. Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 2013;31:545-52.
20. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011;332:687-96.
21. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, et al. Singlecell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry Part A 2015;87:346-56.
22. Obermann EC, Arber C, Jotterand M, Tichelli A, Hirschmann P, Tzankov A. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol 2010;89:663-9.
23. Seedhouse CH, Pallis M, Grundy M, Shang S, Russell NH. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations. Br J Haematol 2009;147:653-61.
24. Darzynkiewicz Z, Halicka HD, Zhao H, Podhorecka M. Cell synchronization by inhibitors of DNA replication induces replication stress and DNA damage response: analysis by flow cytometry. Methods Mol Biol 2011;761:85-96.
25. Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier M-C, Beyene J, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res 2014;38:460-8.
26. Rapin N, Bagger FO, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A, et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood 2014;123:894-904.
27. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005;106:4086-92.
28. Kang LC, Dunphy CH. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med 2006;130:153-7.
29. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005;11:1372-9.
30. Cozzio A, Passegué E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17:3029-35.
31. Pearce DJ, Taussig D, Zibara K, Smith L-L, Ridler CM, Preudhomme C, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006;107:1166-73.
32. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 2000;14:889-97.
33. Monaco G, Konopleva M, Munsell M, Leysath C, Wang R-Y, Jackson CE, et al. Engraftment of acute myeloid leukemia in NOD/SCID Mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004;22:188-201.
34. Schubert M, Herbert N, Taubert I, Ran D, Singh R, Eckstein V, et al. Differential survival of AML subpopulations in NOD/SCID mice. Exp Hematol 2011;39:250-63.e4.
35. Qiu P, Simonds EF, Bendall SC, Gibbs KD, Bruggner RV, Linderman MD, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotech 2011;29:886-91.
36. Sarry J-E, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R?c-deficient mice. J Clin Invest 2011;121:384-95.
37. Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM, et al. Cell of origin determines clinically relevant subtypes of MLLrearranged AML. Leukemia 2013;27:852-60.
38. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
39. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR-. Blood 1998;92: 4325-35.
40. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010;115:1976-84.
41. Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 2010;116:3907-22.
42. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9.
43. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74.
44. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 2005;202:1599-611.
45. Raza A, Preisler H, Lampkin B, Yousuf N, Tucker C, Peters N, et al. Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia. Br J Haematol 1991;79:33-9.
46. Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, et al. Clinical impact of gene mutations and lesions detected by SNParray karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget 2014;5:916-32.
47. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-16.
48. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003;55:61-70.
49. Ornatsky OI, Kinach R, Bandura DR, Lou X, Tanner SD, Baranov VI, et al. Development of analytical methods for multiplex bio-assay with inductively coupled plasma mass spectrometry. J Anal At Spectrom 2008;23:463-9.
50. Finck R, Simonds EF, Jager A, Krishnaswamy S, Sachs K, Fantl W, et al. Normalization of mass cytometry data with bead standards. Cytometry A 2013;83:483-94.